gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2025-35-4-18-26gastro-j-1817Research ArticleОБЗОРЫREVIEWSКалий-конкурентные блокаторы кислотной продукции: новые возможности антисекреторной терапии гастроэзофагеальной рефлюксной болезниPotassium-Competitive Acid Blockers: New Opportunities of Antisecretory Therapy in Gastroesophageal Reflux Diseasehttps://orcid.org/0000-0003-3362-2968ТрухмановА. С.TrukhmanovA. S.

Трухманов Александр Сергеевич — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского

119435, г. Москва, ул. Погодинская, 1, стр. 1

Alexander S. Trukhmanov — Dr. Sci. (Med.), Professor of the Department of Propaedeutics of Internal Medicine, Gastroenterology and Hepatology of the N.V. Sklifosovsky Institute of Clinical Medicine

119435, Moscow, Pogodinskaya str., 1, build. 1

alexander.trukhmanov@gmail.comhttps://orcid.org/0000-0001-7048-0538РумянцеваД. Е.RumyantsevaD. E.

Румянцева Диана Евгеньевна — кандидат медицинских наук, врач отделения гастроэнтерологии Клиники пропедевтики внутренних болезней, гастроэнтерологии и гепатологии им. В.Х. Василенко; ассистент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского

119435, г. Москва, ул. Погодинская, 1, стр. 1

Diana E. Rumyantseva — Cand. Sci. (Med.), Physician at the Department of Gastroenterology, V.Kh. Vasilenko Clinic of Internal Diseases Propaedeutics, Gastroenterology and Hepatology; Assistant of the Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology

119435, Moscow, Pogodinskaya str., 1, build. 1

diana-ryazanceva@yandex.ruФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenovskiy University)Russian Federation2025071020253541826Copyright © Трухманов А.С., Румянцева Д.Е., 20252025Трухманов А.С., Румянцева Д.Е.Trukhmanov A.S., Rumyantseva D.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1817

 Цель обзора: представить современные данные об эффективности и безопасности применения калий-конкурентных блокаторов кислотной продукции (К-КБК) на примере тегопразана у пациентов с гастроэзофагеальной рефлюксной болезнью.Основные положения. Калий-конкурентные блокаторы секреции соляной кислоты по данным проведенных клинических исследований продемонстрировали высокую клиническую эффективность и безопасность у пациентов с гастроэзофагеальной рефлюксной болезнью. Преимуществами данного класса препаратов служат более быстрый и продолжительный антисекреторный эффект, который не зависит от приема пищи, а также отсутствие влияния генетических полиморфизмов изофермента CYP2C19 на фармакокинетику и риска межлекарственных взаимодействий. У пациентов с ночной изжогой представитель К-КБК тегопразан может быть препаратом выбора для достижения более быстрого и продолжительного клинического эффекта и улучшения качества сна. Тегопразан эффективен в отношении ночных кислотных прорывов. В ряде исследований тегопразан превосходил плацебо и ингибиторы протонной помпы (ИПП) в отношении устранения основных симптомов у больных неэрозивной рефлюксной болезнью и ИПП при лечении эрозивного эзофагита. К-КБК рассматриваются как препараты выбора при лечении гастроэзофагеальной рефлюксной болезни, рефрактерной к ИПП.Заключение. Необходимо проведение дальнейших исследований, в том числе в Российской Федерации, подтверждающих высокую эффективность и безопасность тегопразана.

Aim

Aim: to present modern data on the efficacy and safety of using potassium-competitive acid blockers (P-CAB) using tegoprazan as an example in patients with gastroesophageal reflux disease.

Key points

Key points. Potassium-competitive blockers of hydrochloric acid secretion, according to clinical studies, have demonstrated high clinical efficacy and safety in patients with gastroesophageal reflux disease. The advantages of this class of drugs include a faster and longer-lasting antisecretory effect, which does not depend on food intake, as well as the absence of the influence of genetic polymorphisms of the CYP2C19 isoenzyme on pharmacokinetics and the risk of drug interactions. In patients with nocturnal heartburn, the potassium-competitive acid blocker tegoprazan may be the drug of choice to achieve a faster and longer-lasting clinical effect and improve sleep quality. Tegoprazan is effective against nocturnal acid breakthroughs. In several studies, tegoprazan was superior to placebo and proton pump inhibitors (PPIs) in eliminating major symptoms in patients with nonerosive reflux disease and to PPIs in treating erosive esophagitis. P-CABs are considered the drugs of choice in the treatment of gastroesophageal reflux disease refractory to PPIs.

Conclusion

Conclusion. Further studies are needed, including in the Russian Federation, to confirm the high efficacy and safety of tegoprazan.

калий-конкурентные блокаторы кислотной продукциитегопразангастроэзофагеальная рефлюксная болезньэрозивный эзофагитночная изжогаpotassium-competitive acid blockerstegoprazangastroesophageal reflux diseaseerosive esophagitisnocturnal heartburnReferencesNirwan J.S., Hasan S.S., Babar Z.U., Conway B.R., Ghori M.U. Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): Systematic review with meta-analysis. Sci Rep. 2020;10(1):5814. DOI: 10.1038/s41598-020-62795-1Nirwan J.S., Hasan S.S., Babar Z.U., Conway B.R., Ghori M.U. Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): Systematic review with meta-analysis. Sci Rep. 2020;10(1):5814. DOI: 10.1038/s41598-020-62795-1Бордин Д.С., Абдулхаков Р.А., Осипенко М.Ф., Соловьева А.В., Абдулхаков С.Р., Кириленко Н.П. и др. Многоцентровое исследование распространенности симптомов гастроэзофагеальной рефлюксной болезни у пациентов поликлиник в России. Терапевтический архив. 2022;94(1):48–56. DOI: 10.26442/00403660.2022.01.201322Bordin D.S., Abdulkhakov R.А., Osipenko M.F., Solovyeva A.V., Abdulkhakov S.R., Kirilenko N.P., et al. Multicenter study of gastroesophageal reflux disease symptoms prevalence in outpatients in Russia. Terapevticheskii arkhiv. 2022;94(1):48–56. (In Russ.)]. DOI: 10.26442/00403660.2022.01.201322Ивашкин В.Т., Маев И.В., Трухманов А.С., Лапина Т.Л., Сторонова О.А., Зайратьянц О.В. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70– 97. DOI: 10.22416/1382-4376-2020-30-4-70-97Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., Zayratyants O.V., et al. Recommendations of the Russian Gastroenterological Association in diagnosis and treatment of gastroesophageal reflux disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. (In Russ.)]. DOI: 10.22416/1382-4376-2020-30-4-70-97Ивашкин В.Т., Трухманов А.С., Маев И.В., Драпкина О.М., Ливзан М.А., Мартынов А.И. и др. Диагностика и лечение гастроэзофагеальной рефлюксной болезни (Рекомендации Российской гастроэнтерологической ассоциации, Российского научного медицинского общества терапевтов, Российского общества профилактики неинфекционных заболеваний, Научного сообщества по изучению микробиома человека). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(5):111–35. DOI: 10.22416/1382-4376-2024-34-5-111-135Ivashkin V.T., Trukhmanov A.S., Maev I.V., Drapkina O.M., Livzan M.A., Martynov A.I., et al. Diagnosis and treatment of gastroesophageal reflux disease (Clinical guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):111–35. (In Russ.)]. DOI: 10.22416/1382-4376-2024-34-5-111-135Eusebi L.H., Cirota G.G., Zagari R.M., Ford A.C. Global prevalence of Barrett’s oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: A systematic review and meta-analysis. Gut. 2021;70(3):456–63. DOI: 10.1136/gutjnl-2020-321365Eusebi L.H., Cirota G.G., Zagari R.M., Ford A.C. Global prevalence of Barrett’s oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: A systematic review and meta-analysis. Gut. 2021;70(3):456–63. DOI: 10.1136/gutjnl-2020-321365Shaheen N.J., Falk G.W., Iyer P.G., Gerson L.B; Ame- rican College of Gastroenterology. ACG clinical guideline: Diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50. DOI: 10.1038/ajg.2015.322Shaheen N.J., Falk G.W., Iyer P.G., Gerson L.B; Ame- rican College of Gastroenterology. ACG clinical guideline: Diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50. DOI: 10.1038/ajg.2015.322Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021.Malignant neoplasms in Russia in 2020 (morbidity and mortality). Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (eds.). Moscow: P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Center of Radiology, 2021. (In Russ.)].Морошек А.А., Бурмистров М.В., Галкин С.В., Сигал Е.И., Бродер И.А., Иванов А.И. и др. Фармакоэкономический анализ применения комплексного алгоритма для диагностики и лечения осложненной гастроэзофагеальной рефлюксной болезни на фоне грыж пищеводного отверстия диафрагмы. Общественное здоровье и здравоохранение. 2010;4:36–44.Moroshek A.A., Bourmistrov M.V., Galkin S.V., Sigal I.E., Broder I.A., Ivanov A.I., et al. Pharmacoeconomic analysis of application of comprehensive algorithm for diagnostics and treatment of complicated gastroesophageal reflux disease in patients with esophageal hiatus hernia. Public health and healthcare. 2010;4:36–44. (In Russ.)].Dean B.B., Aguilar D., Johnson L.F., McGuigan J.E., Orr W.C., Fass R., et al. Night-time and daytime atypical manifestations of gastro-oesophageal reflux disease: Frequency, severity and impact on health-related quality of life. Aliment Pharmacol Ther. 2008;27(4):327–37. DOI: 10.1111/j.1365-2036.2007.03574.xDean B.B., Aguilar D., Johnson L.F., McGuigan J.E., Orr W.C., Fass R., et al. Night-time and daytime atypical manifestations of gastro-oesophageal reflux disease: Frequency, severity and impact on health-related quality of life. Aliment Pharmacol Ther. 2008;27(4):327–37. DOI: 10.1111/j.1365-2036.2007.03574.xИвашкин В.Т., Маев И.В., Трухманов А.С., Шептулин А.А., Симаненков В.И., Лапина Т.Л. и др. Депрескрайбинг ингибиторов протонной помпы и выбор оптимального препарата данной группы (по результатам научного форума, состоявшегося в рамках XXVI Объединенной Российской гастроэнтерологической недели). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):7–18 DOI: 10.22416/1382-4376-2020-30-6-7-18Ivashkin V.T., Maev I.V., Trukhmanov A.S., Sheptulin A.A., Simanenkov V.I., Lapina T.L., et al. Deprescribing and optimal selection of proton pump inhibitors (Contributions of the 26th United Russian Gastroenterology Week). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(6):7–18. (In Russ.)]. DOI: 10.22416/1382-4376-2020-30-6-7-18Ивашкин В.Т., Маев И.В., Трухманов А.С., Румянцева Д.Е. Современные достижения в диагностике и лечении рефрактерной формы гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2018;90(8):4–12. DOI: 10.26442/terarkh20189084-12Ivashkin V.T., Maev I.V., Trukhmanov A.S., Rumyantseva D.E. Modern achievements in the diagnosis and treatment of the refractory gastroesophageal reflux disease. Terapevticheskii Arkhiv. 2018;90(8):4–12. (In Russ.)]. DOI: 10.26442/terarkh20189084-12Bytzer P., van Zanten S.V., Mattsson H., Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis — a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36(7):635–43. DOI: 10.1111/apt.12007Bytzer P., van Zanten S.V., Mattsson H., Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis — a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36(7):635–43. DOI: 10.1111/apt.12007Cicala M., Emerenziani S., Guarino M.P., Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol. 2013;19(39):6529–35. DOI: 10.3748/wjg.v19.i39.6529Cicala M., Emerenziani S., Guarino M.P., Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol. 2013;19(39):6529–35. DOI: 10.3748/wjg.v19.i39.6529Chey W.D., Inadomi J.M., Booher A.M., Sharma V.K., Fendrick A.M., Howden C.W. Primary-care physicians’ perceptions and practices on the management of GERD: Results of a national survey. Am J Gastroenterol. 2005;100(6):1237–42. DOI: 10.1111/j.1572-0241.2005.41364.xChey W.D., Inadomi J.M., Booher A.M., Sharma V.K., Fendrick A.M., Howden C.W. Primary-care physicians’ perceptions and practices on the management of GERD: Results of a national survey. Am J Gastroenterol. 2005;100(6):1237–42. DOI: 10.1111/j.1572-0241.2005.41364.xGunaratnam N.T., Jessup T.P., Inadomi J., Lascewski D.P. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23(10):1473–7. DOI: 10.1111/j.1365-2036.2006.02911.xGunaratnam N.T., Jessup T.P., Inadomi J., Lascewski D.P. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23(10):1473–7. DOI: 10.1111/j.1365-2036.2006.02911.xRonkainen J., Aro P., Storskrubb T., Johansson S.E., Lind T., Bolling-Sternevald E., et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report. Scand J Gastroenterol. 2005;40(3):275–85. DOI: 10.1080/00365520510011579Ronkainen J., Aro P., Storskrubb T., Johansson S.E., Lind T., Bolling-Sternevald E., et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report. Scand J Gastroenterol. 2005;40(3):275–85. DOI: 10.1080/00365520510011579Richter J.E., Kahrilas P.J., Johanson J., Maton P., Breiter J.R., Hwang C., et al; Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol. 2001;96(3):656–65. DOI: 10.1111/j.15720241.2001.3600_b.xRichter J.E., Kahrilas P.J., Johanson J., Maton P., Breiter J.R., Hwang C., et al; Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol. 2001;96(3):656–65. DOI: 10.1111/j.15720241.2001.3600_b.xLightdale C.J., Schmitt C., Hwang C., Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci. 2006;51(5):852–7. DOI: 10.1007/s10620-005-9071-3Lightdale C.J., Schmitt C., Hwang C., Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci. 2006;51(5):852–7. DOI: 10.1007/s10620-005-9071-3Higuchi K., Joh T., Nakada K., Haruma K. Is proton pump inhibitor therapy for reflux esophagitis sufficient?: A large real-world survey of Japanese patients. Intern Med. 2013;52(13):1447–54. DOI: 10.2169/internalmedicine.52.0349Higuchi K., Joh T., Nakada K., Haruma K. Is proton pump inhibitor therapy for reflux esophagitis sufficient?: A large real-world survey of Japanese patients. Intern Med. 2013;52(13):1447–54. DOI: 10.2169/internalmedicine.52.0349Katz P.O., Johnson D.A., Levine D., Röhss K., Junghard O., Astrand M., et al. A model of healing of Los Angeles grades C and D reflux oesophagitis: Is there an optimal time of acid suppression for maximal healing? Aliment Pharmacol Ther. 2010;32(3):443–7. DOI: 10.1111/j.1365-2036.2010.04367.xKatz P.O., Johnson D.A., Levine D., Röhss K., Junghard O., Astrand M., et al. A model of healing of Los Angeles grades C and D reflux oesophagitis: Is there an optimal time of acid suppression for maximal healing? Aliment Pharmacol Ther. 2010;32(3):443–7. DOI: 10.1111/j.1365-2036.2010.04367.xPeghini P.L., Katz P.O., Bracy N.A., Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93(5):763–7. DOI: 10.1111/j.1572-0241.1998.221_a.xPeghini P.L., Katz P.O., Bracy N.A., Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93(5):763–7. DOI: 10.1111/j.1572-0241.1998.221_a.xHan S., Choi H.Y., Kim Y.H., Nam J.Y., Kim B., Song G.S., et al. Randomised clinical trial: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019;50(7):751–9. DOI: 10.1111/apt.15438Han S., Choi H.Y., Kim Y.H., Nam J.Y., Kim B., Song G.S., et al. Randomised clinical trial: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019;50(7):751–9. DOI: 10.1111/apt.15438Han S., Choi H.Y., Kim Y.H., Choi S., Kim S., Nam J.Y., et al. Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: A randomized crossover study. Gut Liver. 2023;17(1):92–9. DOI: 10.5009/gnl220050Han S., Choi H.Y., Kim Y.H., Choi S., Kim S., Nam J.Y., et al. Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: A randomized crossover study. Gut Liver. 2023;17(1):92–9. DOI: 10.5009/gnl220050Takahashi N., Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther. 2018;364(2):275–86. DOI: 10.1124/jpet.117.244202Takahashi N., Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther. 2018;364(2):275–86. DOI: 10.1124/jpet.117.244202Han S., Choi H.Y., Kim Y.H., Nam J.Y., Kim B., Song G.S., et al. Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan. Clin Ther. 2021;43(8):1371–80. DOI: 10.1016/j.clinthera.2021.06.007Han S., Choi H.Y., Kim Y.H., Nam J.Y., Kim B., Song G.S., et al. Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan. Clin Ther. 2021;43(8):1371–80. DOI: 10.1016/j.clinthera.2021.06.007Yang E., Kim S., Kim B., Kim B., Kim Y., Park S.S., et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 2022;88(7):3288–96. DOI: 10.1111/bcp.15268Yang E., Kim S., Kim B., Kim B., Kim Y., Park S.S., et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 2022;88(7):3288–96. DOI: 10.1111/bcp.15268Han G.H., Kim S.J., Ko W.K., Hong J.B., Sheen S.H., Cho M.J., et al. Anti-Inflammatory effects of tegoprazan in lipopolysaccharide-stimulated bone-marrow- derived macrophages. Int J Mol Sci. 2023;24(19):14589. DOI: 10.3390/ijms241914589Han G.H., Kim S.J., Ko W.K., Hong J.B., Sheen S.H., Cho M.J., et al. Anti-Inflammatory effects of tegoprazan in lipopolysaccharide-stimulated bone-marrow- derived macrophages. Int J Mol Sci. 2023;24(19):14589. DOI: 10.3390/ijms241914589Kim S.Y., Yoon J.H., Jung D.H., Kim G.H., Kim C.H., Lee S.K. Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/ Caspase-1/GSDMD pyroptotic pathway. Front Immunol. 2024;15:1410904. DOI: 10.3389/fimmu.2024.1410904Kim S.Y., Yoon J.H., Jung D.H., Kim G.H., Kim C.H., Lee S.K. Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/ Caspase-1/GSDMD pyroptotic pathway. Front Immunol. 2024;15:1410904. DOI: 10.3389/fimmu.2024.1410904Kim M.G., Im Y.J., Lee J.H., Kim E.Y., Yeom S.W., Kim J.S. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Front Med (Lausanne). 2023;9:1076356. DOI: 10.3389/fmed.2022.1076356Kim M.G., Im Y.J., Lee J.H., Kim E.Y., Yeom S.W., Kim J.S. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Front Med (Lausanne). 2023;9:1076356. DOI: 10.3389/fmed.2022.1076356Kim J.S., Seo S.I., Kang S.H., Lee S.K., Kim A.R., Park H.W., et al. Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: A multicenter double-blind randomized controlled trial. J Neurogastroenterol Motil. 2023;29(1):58–64. DOI: 10.5056/jnm22104Kim J.S., Seo S.I., Kang S.H., Lee S.K., Kim A.R., Park H.W., et al. Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: A multicenter double-blind randomized controlled trial. J Neurogastroenterol Motil. 2023;29(1):58–64. DOI: 10.5056/jnm22104Kim S.H., Cho K.B., Chun H.J., Lee S.W., Kwon J.G., Lee D.H., et al. Randomised clinical trial: Comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther. 2021;54(4):402–11. DOI: 10.1111/apt.16477Kim S.H., Cho K.B., Chun H.J., Lee S.W., Kwon J.G., Lee D.H., et al. Randomised clinical trial: Comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther. 2021;54(4):402–11. DOI: 10.1111/apt.16477Wang Y., Dai X., Zhang X. Network meta-analysis of comparing different dosages of potassium-competitive acid blocker with proton-pump inhibitor in acid-related disorders. Clin Transl Gastroenterol. 2024;15(11):e00776. DOI: 10.14309/ctg.0000000000000776Wang Y., Dai X., Zhang X. Network meta-analysis of comparing different dosages of potassium-competitive acid blocker with proton-pump inhibitor in acid-related disorders. Clin Transl Gastroenterol. 2024;15(11):e00776. DOI: 10.14309/ctg.0000000000000776Seo S., Jung H.K., Gyawali C.P., Lee H.A., Lim H.S., Jeong E.S., et al. Treatment response with potassium-competitive acid blockers based on clinical phenotypes of gastroesophageal reflux disease: A systematic literature review and meta-analysis. J Neurogastroenterol Motil. 2024;30(3):259–71. DOI: 10.5056/jnm24024Seo S., Jung H.K., Gyawali C.P., Lee H.A., Lim H.S., Jeong E.S., et al. Treatment response with potassium-competitive acid blockers based on clinical phenotypes of gastroesophageal reflux disease: A systematic literature review and meta-analysis. J Neurogastroenterol Motil. 2024;30(3):259–71. DOI: 10.5056/jnm24024Zhuang Q., Chen S., Zhou X., Jia X., Zhang M., Tan N., et al. Comparative efficacy of P-CAB vs proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis. Am J Gastroenterol. 2024;119(5):803–13. DOI: 10.14309/ajg.0000000000002714Zhuang Q., Chen S., Zhou X., Jia X., Zhang M., Tan N., et al. Comparative efficacy of P-CAB vs proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis. Am J Gastroenterol. 2024;119(5):803–13. DOI: 10.14309/ajg.0000000000002714Zhou X., Duan H., Li Q., Wang Q., Sun X. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: A systematic review and meta-analysis. Scand J Gastroenterol. 2024;59(7):788–97. DOI: 10.1080/00365521.2024.2349638Zhou X., Duan H., Li Q., Wang Q., Sun X. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: A systematic review and meta-analysis. Scand J Gastroenterol. 2024;59(7):788–97. DOI: 10.1080/00365521.2024.2349638Lee K.J., Son B.K., Kim G.H., Jung H.K., Jung H.Y., Chung I.K., et al. Randomised phase 3 trial: Tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(7):864–72. DOI: 10.1111/apt.15185Lee K.J., Son B.K., Kim G.H., Jung H.K., Jung H.Y., Chung I.K., et al. Randomised phase 3 trial: Tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(7):864–72. DOI: 10.1111/apt.15185Zhu H., Xue Q., Song Y., Zhang Z., Li X., Lyu S., et al. Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase – trial. Chin Med J (Engl). 2024. DOI: 10.1097/CM9.0000000000003276Zhu H., Xue Q., Song Y., Zhang Z., Li X., Lyu S., et al. Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase – trial. Chin Med J (Engl). 2024. DOI: 10.1097/CM9.0000000000003276Cho Y.K., Kim J.H., Kim H.S., Kim T.O., Oh J.H., Choi S.C., et al. Randomised clinical trial: Comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023;57(1):72–80. DOI: 10.1111/apt.17255Cho Y.K., Kim J.H., Kim H.S., Kim T.O., Oh J.H., Choi S.C., et al. Randomised clinical trial: Comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023;57(1):72–80. DOI: 10.1111/apt.17255Shin C.M., Choi S.C., Cho J.W., Kim S.Y., Lee O.J., Kim D.H., et al. Comparison of tegoprazan and lansoprazole in patients with erosive esophagitis up to 4 weeks: A multi-center, randomized, double-blind, active-comparator phase 4 trial. Neurogastroenterol Motil. 2025;37(1):e14969. DOI: 10.1111/nmo.14969Shin C.M., Choi S.C., Cho J.W., Kim S.Y., Lee O.J., Kim D.H., et al. Comparison of tegoprazan and lansoprazole in patients with erosive esophagitis up to 4 weeks: A multi-center, randomized, double-blind, active-comparator phase 4 trial. Neurogastroenterol Motil. 2025;37(1):e14969. DOI: 10.1111/nmo.14969Liu Y., Gao Z., Hou X. Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: A systematic review and network meta-analysis. Therap Adv Gastroenterol. 2024;17:17562848241251567. DOI: 10.1177/17562848241251567Liu Y., Gao Z., Hou X. Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: A systematic review and network meta-analysis. Therap Adv Gastroenterol. 2024;17:17562848241251567. DOI: 10.1177/17562848241251567Iwakiri K., Fujiwara Y., Manabe N., Ihara E., Kuribayashi S., Akiyama J., et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267–85. DOI: 10.1007/s00535-022-01861-zIwakiri K., Fujiwara Y., Manabe N., Ihara E., Kuribayashi S., Akiyama J., et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267–85. DOI: 10.1007/s00535-022-01861-zJung H.K., Tae C.H., Song K.H., Kang S.J., Park J.K., Gong E.J., et al.; Korean Society of Neurogastroenterology and Motility. 2020 Seoul Consensus on the diagnosis and management of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2021;27(4):453–81. DOI: 10.5056/jnm21077Jung H.K., Tae C.H., Song K.H., Kang S.J., Park J.K., Gong E.J., et al.; Korean Society of Neurogastroenterology and Motility. 2020 Seoul Consensus on the diagnosis and management of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2021;27(4):453–81. DOI: 10.5056/jnm21077Goh K.L., Lee Y.Y., Leelakusolvong S., Makmun D., Maneerattanaporn M., Quach D.T., et al. Consensus statements and recommendations on the management of mild-to-moderate gastroesophageal reflux disease in the Southeast Asian region. JGH Open. 2021;5(8):855–63. DOI: 10.1002/jgh3.12602Goh K.L., Lee Y.Y., Leelakusolvong S., Makmun D., Maneerattanaporn M., Quach D.T., et al. Consensus statements and recommendations on the management of mild-to-moderate gastroesophageal reflux disease in the Southeast Asian region. JGH Open. 2021;5(8):855–63. DOI: 10.1002/jgh3.12602

The authors declare that there are no conflicts of interest present.